ARTEMISMEDNSEArtemis Medicare Services LimitedMinimalNeutral
Announced Fri, 8 May · 21:01 IST

Monitoring Agency Report for the quarter ended March 31, 2026

ARTEMISMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.5%1-day move
₹266.00
prior close
₹272.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.3+2.7+3.3+3.8+1.5+3.8+4.2+5.4+2.3+5.3+2.3-4.5+4.7
Up moveDown movePending
AI summary

Artemis Medicare Services has filed its Q4 FY26 monitoring agency report by CARE Ratings Limited, covering the utilisation of Rs. 330 crore raised via a preferential issue (approved under SEBI ICDR Regulations). As of March 31, 2026, Rs. 74.62 crore (22.6%) has been deployed out of the total issue size. The company has signed a Medical Services Agreement with Vidaas Kausahlya Memorial Healthcare Entity and advanced Rs. 74.62 crore as part of the arrangement. The remaining Rs. 255.38 crore is still unutilised and parked in fixed deposits and a monitoring account. The Audit Committee reviewed the report on May 8, 2026. The intended use was for acquisition, expansion, and capital expenditure requirements of the company and its subsidiaries.

Likely market impact

The slow pace of fund utilisation (~22.6% deployed in over two years sincepril 2024) may signal delayed M&A or expansion execution, which investors should monitor closely. The unutilised amount is temporarily deployed in liquid instruments, which is compliant but raises execution timeline questions.